PTC Therapeutics: Upside In Rare Disease Innovation

Group 1 - PTC Therapeutics is facing declining revenues and profitability but is preparing for a turnaround [1] - The company has potential asymmetric upside due to several regulatory catalysts expected in 2025, including the FDA review of vatiquinone for Friedreich's ataxia and sepiapterin [1]